Determine Risk for Cardiovascular Disease

Personalized Genetic Testing provides an invaluable service to physicians and patients throughout the U.S.

Thousands of Tests Performed

Providing doctors with the information needed to determine the best medicines and treatments for each of their patients.

20+ Years Experience

Experience in biotechnology, pharmaceutical, hematology, flow cytometry, clinical molecular biology, immunology, and chemistry industries.

Fast 5-Day Turnaround

Using the latest technologies from the leaders in the industry, our process is 3 times faster than competitor’s analysis methods.

Accurate Reporting

Through Coriell Institute, backed by over 60 years of research experience providing the quality control required for validation in pharmacogenetics testing.

PGT’s MTHFR genotyping supports doctors in determining the risk of hyperhomocysteinemia, which is a known risk factor for cardiovascular disease.

Methylenetetrahydrofolate Reductase (MTHFR)

MTHFR gene testing determined that the MTHFR (Methylenetetrahydrofolate Reductase) enzyme catalyzes the formation of 5-methyltetrahydrofolate, the main circulating form of active folate. The absence of active folate leads to accumulation of plasma homocysteine. The 677 C>T polymorphism of MTHFR leads to decreased MTHFR enzymatic activity and elevated homocysteine. The 1298 A>C polymorphism is associated with significant increases plasma homocysteine levels only when in combination with the 677 C>T polymorphism. High plasma homocysteine has been revealed to be a risk factor for atherosclerotic heart disease, myocardial infarction, cerebrovascular disease, and venous thrombosis. MTHFR lab testing It has been reported, associations between the 677 C>T polymorphism and increased risk of fetal neural tube defects in pregnant women, increased risk for methotrexate toxicity, and augmented chemosensitivity of colon and breast cancers to 5fluorouracil.